Clinical characteristics and risk factors of drug‐induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis-Reference-Cited by-同舟云学术

Clinical characteristics and risk factors of drug‐induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis

Published:2020-04 Issue:6 Volume:11 Page:1495-1502
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Koshikawa Ken¹,Terada Jiro¹^ORCID,Abe Mitsuhiro¹,Iwasawa Shunichiro¹,Sakayori Masashi¹,Yoshioka Keiichiro¹,Hirasawa Yasutaka¹,Kasai Hajime¹,Kawasaki Yohei²,Tsushima Kenji³,Tatsumi Koichiro¹

Affiliation:

1. Department of Respirology, Graduate School of Medicine Chiba University Chiba Japan

2. Biostatistics Section Clinical Research Center, Chiba University Hospital Chiba Japan

3. Department of Pulmonary Medicine International University of Health and Welfare, School of Medicine, Narita city Chiba Japan

Funder

The Intractable Respiratory Diseases and Pulmonary Hypertension Research Group, the Ministry of Health, Labor and Welfare

The Japan Agency for Medical Research and Development

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13416

Reference20 articles.

1. ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer

2. ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development

3. ALK, Lung Cancer, and Personalized Therapy: Portent of the Future?

4. Severe Acute Interstitial Lung Disease After Crizotinib Therapy in a Patient With EML4-ALK–Positive Non–Small-Cell Lung Cancer

5. Acute interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer after crizotinib therapy

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characteristics and risk factors for drug-induced lung injury in hospitalized patients: A matched case-control study;2023-08-03

2. miR-199a: A Tumor Suppressor with Noncoding RNA Network and Therapeutic Candidate in Lung Cancer;International Journal of Molecular Sciences;2022-07-31

3. Pulmonary toxicity in driver gene positive non-small cell lung cancer therapy;Current Medical Research and Opinion;2022-06-15

4. Interstitial lung disease associated with combination therapy of dabrafenib and trametinib in metastatic BRAFV600E-mutated poorly differentiated thyroid cancer: A case report and review of the literature;Int. Journal of Clinical Pharmacology and Therapeutics;2022-05-01

5. Switching to an alternative ALK-inhibitor after alectinib-induced pneumonitis resulted in resolution of this adverse event;Current Problems in Cancer: Case Reports;2020-12